AMAG Pharmaceuticals

374 articles about AMAG Pharmaceuticals

• AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme (ferumoxytol injection)

  2/5/2018

  This sNDA approval immediately doubles the number of patients who could benefit from Feraheme to include both CKD and non-CKD patients.

• 

  3 FDA Decisions to Look Out for in February

  2/1/2018

  Here is a look at a few important regulatory events scheduled for the month of February.

• AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance

  1/8/2018

  A live audio webcast of the presentation and following breakout session will be accessible through the Investors section of AMAG’s website.

• 

  5 Massachusetts Biotechs That Tanked More Than 60% in 2017

  1/2/2018

  This is definitely a list few, if any, companies want to be on.

• New Patent Issued to AMAG Pharma Entitled "Methods of Reducing Risk of Preterm Birth"

  12/20/2017

  If approved, the auto-injector will join the Makena portfolio, which also includes the FDA-approved intramuscular injection.

• AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children With Cerebral Palsy

  11/8/2017

  More than one-third of study participants in Phase 2 Study were Cord Blood Registry (CBR) clients.

• Hypophosphatemia Data From AMAG Phase III Trial Presented at the American Society of Nephrology

  11/6/2017

  This study was comprised of approximately 2,000 adult patients with iron deficiency anemia regardless of the cause who had failed or could not tolerate oral iron therapy

• AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights

  11/2/2017

  Total GAAP revenue for the third quarter of 2017 increased to $153.7 million, 7% higher than the same period last year.

• AMAG Pharmaceuticals to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 2, 2017 at 8:00 a.m. ET

  10/19/2017

  Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

• AMAG Appoints Tracy Palmer Berns As Chief Compliance Officer

  9/29/2017

• AMAG Appoints Laura Williams, M.D. As Senior Vice President Of Clinical Development

  9/7/2017

• AMAG Announces FDA Filing Acceptance And Six-Month Review Of Feraheme (Ferumoxytol) For The Treatment Of All Adult Patients With Iron Deficiency Anemia

  8/31/2017

• AMAG Appoints Oscar Sanchez As Vice President Of Quality

  8/8/2017

• AMAG Completes Feraheme (Ferumoxytol) FDA Submission For The Treatment Of All Adult Patients With Iron Deficiency Anemia

  8/3/2017

• AMAG Announces Second Quarter 2017 Financial Results And Provides Corporate Update

  8/3/2017

• AMAG Launches Intrarosa (Prasterone) In The U.S. – A Novel Product To Treat Moderate To Severe Dyspareunia Due To Menopause

  7/24/2017

• AMAG To Host Second Quarter 2017 Financial Results Conference Call And Webcast On Thursday, August 3, 2017 At 8:00 A.M. ET

  7/20/2017

• AMAG Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Makena® (Hydroxyprogesterone Caproate Injection) Subcutaneous Auto-Injector

  6/26/2017

• AMAG Announces First Patient Enrolled In Phase IIb/IIIa Digoxin Immune Fab Study Conducted By Velo Bio

  6/1/2017

• AMAG Appoints Helen Milton, Ph.D. As Vice President Of Regulatory Affairs

  5/16/2017